跳至主要内容
临床试验/EUCTR2015-003947-21-PL
EUCTR2015-003947-21-PL进行中(未招募)1 期

’Dose dependent pain relieving efficacy and local tolerability of diclofenac oromucosal spray in the treatment of sore throat: A multicenter, parallel-group, double-blind, placebo controlled and randomized clinical study’’

FARMAKA Srl0 个研究点目标入组 180 人开始时间: 2015年11月17日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • ?Male or female outpatients
  • ?Aged 18 – 75 years
  • ?Evidence of acute viral tonsillopharyngitis not requiring antibiotic treatment as diagnosed by physician
  • ?Pain at swallowing (odynophagia) not less than 50 mm on a 100 mm VAS scale
  • ?Tonsillo-Pharyngitis Score (TPS) >6 points at baseline.
  • ?Disease onset within 48 hours prior to study inclusion, medically untreated.
  • ?If female of childbearing potential:
  • ?Have maintained reliable birth control (oral contraceptive, IUDs ) for at least one month before the enrollment and agree to maintain it throughout the study and
  • ?with negative pregnancy test (urine)
  • ?Subject who, in the opinion of the investigator, would understand the meaning of the information sheet, would be co-operative and sufficiently reliable to use the medication as instructed, complete the diary and return for scheduled visits including assurance of availability for follow¬-up call.
  • ?Subject has provided signed written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 180
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 180

排除标准

  • ?Known hypersensitivity to any component of the study medication and / or paracetamol
  • ?Hypersensivity to acetylsalicylic acid and any NSAIDs
  • ?Recognized alteration in hepatic or renal function or positive history of gastrointestinal disorders
  • ?Recognized glucose 6 dehydrogenase deficit
  • ?Streptococcal throat infection - positive finding on Strep Test in commercial presentation available on the Polish market
  • ?Subject undergone to any oromucosal surgery 30 days before the enrollment date
  • ?Subject mentally not capable of adhering to the protocol
  • ?Subjects suffering from depression, epilepsy or other psychological disorders
  • ?Known impaired kidney, liver or lung function
  • ?Bronchopneumonia
  • ?Sore throat had been present for more than 2 days
  • ?Cardiac malfunction
  • ?Hypertension: Diastolic Blood Pressure >90 mm Hg or Systolic Blood Pressure >140 mm Hg unless stable and under adequate therapy
  • ?Hypotension: Systolic Blood pressure < 100 mm Hg
  • ?Bradycardia: frequency < 45 beats / min
  • ?Gastrointestinal disorders, especially ulcers and acute or chronic gastritis
  • ?Malignant disease
  • ?Pathological changes (open wounds) in oral cavity
  • ?Suspected peritonsillar abscess
  • ?Use of any pastille, lozenge, spray or topical medication containing local anesthetic, disinfectant or anti-inflammatory within 15 hours prior to study entry (5 x elimination half-life)
  • ?Use of any long-acting or slow-release analgesic, including NSAIDs, within 24 hours of study entry
  • ?Pregnant or lactating women
  • ?Women of childbearing potential who are not taking adequate contraception
  • ?The patient is not able to fully comply with trial requirements
  • ?Participation in any other clinical trial within the previous 30 days
  • ?Drug addiction
  • ?Nicotine: more than 20 cigarettes per day, (smoking is prohibited during the first hour after the application of the IMP / placebo)
  • ?Alcohol abuse(no alcohol intake during the study!!!)
  • ?Known positive HIV-infection

研究者

发起方
FARMAKA Srl

相似试验